Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433201 | 1.00 | DRD2 (0.54) | DRD2DRD4DRD3ACHEMAOB | |
| SCHEMBL1039407 | 0.95 | DRD2 (0.52) | DRD2DRD4DRD3ACHEMAOB | |
| SCHEMBL30712216 | 0.94 | DRD2 (0.57) | DRD2DRD4DRD3ACHEMAOB | |
| SCHEMBL19732216 | 0.94 | DRD2 (0.57) | DRD2DRD4DRD3ACHEMAOB | |
| SCHEMBL6586939 | 0.92 | DRD2 (0.49) | DRD2DRD4DRD3ACHEMAOB | |
| SCHEMBL8860585 | 0.89 | PDE3B (0.52) | DRD2DRD4DRD3 | |
| SCHEMBL18507832 | 0.88 | DRD2 (0.52) | DRD2DRD4DRD3ACHEMAOB | |
| SCHEMBL15854760 | 0.86 | DRD2 (0.52) | DRD2DRD4DRD3ACHEMAOB | |
| SCHEMBL14772949 | 0.86 | DRD2 (0.52) | DRD2DRD4DRD3ACHEMAOB | |
| SCHEMBL18507944 | 0.86 | DRD2 (0.52) | DRD2DRD4DRD3ACHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118067866-A | Method for detecting brexpiprazole intermediate and isomer related substances thereof | 北京万全德众医药生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117645602-A | Impurity removal method of bripiprazole intermediate and preparation method of bripiprazole | 黑龙江珍宝岛药业股份有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-112858524-B | Detection method and application of brexpiprazole related substance | 丽珠集团新北江制药股份有限公司 | 2022-12-20 | — | — | CN | claimed |
| CN-112858524-A | Detection method and application of brexpiprazole related substance | 丽珠集团新北江制药股份有限公司 | 2021-05-28 | — | — | CN | claimed |
| CN-104844585-B | Method for preparing brexpiprazole | 重庆医药工业研究院有限责任公司 | 2021-05-11 | — | — | CN | claimed |
| CN-109970705-B | Method for preparing brexpiprazole intermediate and brexpiprazole by using cheap metal copper | 浙江工业大学 | 2021-02-09 | — | — | CN | claimed |
| US-20260130904-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| US-20250241909-A1 | INJECTABLE FORMULATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-07-31 | — | — | US | disclosed |
| US-20250121065-A1 | INJECTABLE PREPARATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-04-17 | — | — | US | disclosed |
| CN-118817888-A | Method for detecting related substances of bripiprazole | 浙江国邦药业有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240277702-A1 | INJECTABLE FORMULATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| US-12016927-B2 | Injectable preparation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-25 | — | — | US | disclosed |
| CN-118067866-A | Method for detecting brexpiprazole intermediate and isomer related substances thereof | 北京万全德众医药生物技术有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-06-23 | — | — | US | disclosed |
| US-7888362-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| EP-1869025-B1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| CN-101302214-A | Aralkyl piperidine (piperazidine) derivate and use thereof in mental disease treatment | JIANGSU GUOHUA INVEST CO LTD (CN) | 2008-11-12 | — | — | CN | disclosed |
| EP-1869025-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006112464-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016927-B2 | Injectable preparation | TNF, IL1B, F12 | DRD2 782/4885DRD4 927/4885DRD3 1299/4885 |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885DRD4 91/4885DRD3 154/4885 |
| US-20250241909-A1 | INJECTABLE FORMULATION | SLC47A1, SLC18A1, ABCB11 | DRD2 2024/4885DRD4 1857/4885DRD3 2724/4885 |
| US-20260130904-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | EBP, SIGMAR1, EP300 | DRD2 163/4885DRD4 191/4885DRD3 387/4885 |
| US-20240277702-A1 | INJECTABLE FORMULATION | SLC47A1, SLC18A1, ABCB11 | DRD2 2024/4885DRD4 1857/4885DRD3 2724/4885 |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | DRD2 126/4885DRD4 91/4885DRD3 154/4885 |
| US-20250121065-A1 | INJECTABLE PREPARATION | TNF, IL1B, F12 | DRD2 785/4885DRD4 932/4885DRD3 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.